Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab

IF 3.9 3区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Hepatology Research Pub Date : 2024-06-15 DOI:10.1111/hepr.14084

Kei Endo, Keisuke Kakisaka, Tamami Abe, Kenji Yusa, Ippeki Nakaya, Takuya Watanabe, Hiroaki Abe, Akiko Suzuki, Yuichi Yoshida, Takayoshi Oikawa, Akio Miyasaka, Hidekatsu Kuroda, Takayuki Matsumoto

{"title":"Grip strength complements performance status in assessing general condition in patients with unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab","authors":"Kei Endo, Keisuke Kakisaka, Tamami Abe, Kenji Yusa, Ippeki Nakaya, Takuya Watanabe, Hiroaki Abe, Akiko Suzuki, Yuichi Yoshida, Takayoshi Oikawa, Akio Miyasaka, Hidekatsu Kuroda, Takayuki Matsumoto","doi":"10.1111/hepr.14084","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>An accurate assessment of the general condition of patients with hepatocellular carcinoma (HCC) is essential. We evaluated the impact of grip strength (GS) and Eastern Cooperative Oncology Group Performance Status (ECOG-PS) on the clinical outcomes of patients with unresectable HCC (u-HCC) treated with atezolizumab plus bevacizumab.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This observational cohort study analyzed 89 patients with u-HCC treated with atezolizumab plus bevacizumab between October, 2020 and October, 2023. A Cox proportional hazards model and Kaplan–Meier curve were used to identify the prognostic factors associated with survival outcomes.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>There were 33 patients who had low GS and 16 had an ECOG-PS ≥1. The frequency of patients with low GS increased as the ECOG-PS score increased. The overall survival of the normal GS group was significantly higher than that of the low GS group (<i>p</i> < 0.01). There was no significant difference in progression-free survival between the normal GS group and low-GS group (<i>p</i> = 0.28). Among the patients in the ECOG-PS 0 groups, the overall survival in the normal GS group was significantly higher than that in the low GS group (<i>p</i> < 0.01). A multivariate analysis revealed that modified albumin-bilirubin 2b (HR 2.24; 95% confidence interval [CI] 1.06–4.73), α-fetoprotein ≥100 ng/mL (HR 2.35; 95% CI 1.20–4.58), and low GS (HR 2.87; 95% CI 1.31–6.27) were independently associated with a poor overall survival.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The present study demonstrated that GS is a sensitive marker for detecting a subclinical decline in the general condition and is therefore a potential predictor of the outcome of u-HCC patients treated with atezolizumab plus bevacizumab.</p>\n </section>\n </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"54 12","pages":"1158-1173"},"PeriodicalIF":3.9000,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatology Research","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/hepr.14084","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

An accurate assessment of the general condition of patients with hepatocellular carcinoma (HCC) is essential. We evaluated the impact of grip strength (GS) and Eastern Cooperative Oncology Group Performance Status (ECOG-PS) on the clinical outcomes of patients with unresectable HCC (u-HCC) treated with atezolizumab plus bevacizumab.

Methods

This observational cohort study analyzed 89 patients with u-HCC treated with atezolizumab plus bevacizumab between October, 2020 and October, 2023. A Cox proportional hazards model and Kaplan–Meier curve were used to identify the prognostic factors associated with survival outcomes.

Results

There were 33 patients who had low GS and 16 had an ECOG-PS ≥1. The frequency of patients with low GS increased as the ECOG-PS score increased. The overall survival of the normal GS group was significantly higher than that of the low GS group (p < 0.01). There was no significant difference in progression-free survival between the normal GS group and low-GS group (p = 0.28). Among the patients in the ECOG-PS 0 groups, the overall survival in the normal GS group was significantly higher than that in the low GS group (p < 0.01). A multivariate analysis revealed that modified albumin-bilirubin 2b (HR 2.24; 95% confidence interval [CI] 1.06–4.73), α-fetoprotein ≥100 ng/mL (HR 2.35; 95% CI 1.20–4.58), and low GS (HR 2.87; 95% CI 1.31–6.27) were independently associated with a poor overall survival.

Conclusions

The present study demonstrated that GS is a sensitive marker for detecting a subclinical decline in the general condition and is therefore a potential predictor of the outcome of u-HCC patients treated with atezolizumab plus bevacizumab.

Abstract Image

查看原文本刊更多论文

在评估接受阿特珠单抗和贝伐珠单抗治疗的不可切除肝细胞癌患者的一般状况时，握力与表现状态相辅相成。

目的：准确评估肝细胞癌（HCC）患者的一般状况至关重要。我们评估了握力（GS）和东部合作肿瘤学组表现状态（ECOG-PS）对阿替佐珠单抗联合贝伐单抗治疗的不可切除型肝癌（u-HCC）患者临床预后的影响：这项观察性队列研究分析了2020年10月至2023年10月期间接受atezolizumab加贝伐单抗治疗的89例u-HCC患者。研究采用Cox比例危险模型和Kaplan-Meier曲线来确定与生存结果相关的预后因素：低GS患者有33例，ECOG-PS≥1的患者有16例。正常 GS 组的总生存率明显高于低 GS 组（P 结论：正常 GS 组的总生存率明显高于低 GS 组：本研究表明，GS是检测全身状况亚临床衰退的敏感指标，因此是阿特珠单抗联合贝伐单抗治疗 u-HCC 患者预后的潜在预测指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatology Research 医学-胃肠肝病学

CiteScore

8.30

自引率

14.30%

发文量

124

审稿时长

1 months

期刊介绍： Hepatology Research (formerly International Hepatology Communications) is the official journal of the Japan Society of Hepatology, and publishes original articles, reviews and short comunications dealing with hepatology. Reviews or mini-reviews are especially welcomed from those areas within hepatology undergoing rapid changes. Short communications should contain concise definitive information.